research use only
Cat.No.S2073
| Related Targets | CFTR CRM1 CD markers AChR Calcium Channel Sodium Channel GABA Receptor TRP Channel ATPase GluR |
|---|---|
| Other Potassium Channel Inhibitors | Nicorandil TRAM-34 Sophocarpine ML133 HCl Hydralazine HCl Gliquidone PAP-1 VU0071063 Apamin A2793 |
|
In vitro |
Ethanol : 2 mg/mL
DMSO
: Insoluble
Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 668.88 | Formula | (C19H24NO3)2.Ca |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 207844-01-7, 145525-41-3 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | KAD-1229 | Smiles | C1CCC2CN(CC2C1)C(=O)CC(CC3=CC=CC=C3)C(=O)[O-].C1CCC2CN(CC2C1)C(=O)CC(CC3=CC=CC=C3)C(=O)[O-].[Ca+2] | ||
| Targets/IC50/Ki |
Potassium channel
|
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04349696 | Completed | Type 2 Diabetes Mellitus|Liver Dysfunction |
Orient Europharma Co. Ltd. |
February 11 2014 | Phase 4 |
| NCT01403818 | Completed | Healthy|Pharmacokinetics of ASP1941|Pharmacokinetics of Mitiglinide |
Astellas Pharma Inc |
June 2011 | Phase 1 |
| NCT00566865 | Completed | Type 2 Diabetes Mellitus |
Elixir Pharmaceuticals |
November 2007 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.